Trends

The Anatomy of a Startup Graveyard — And Why the Sector You Pick Isn't What Saves You

Executive Summary (TL;DR): Healthcare & biotech, fintech, and food & agriculture together account for roughly 40% of recent VC-backed startup shutdowns, each failing for a different structural reason — clinical risk, funding-cycle risk, and trend-driven capital. Our own Q3 2026 founder data shows current idea submissions concentrated in AI & ML instead of these historically fragile categories, which sounds like good news. It isn't: 71.4% of those ideas still scored in our lowest viability band. Sector doesn't predict survival. An unvalidated customer and an unclear monetization path do — regardless of the label on the pitch deck. Validate your idea before you build it.

Which Sectors Fail Most, and Why It's Not Random

Industry analysis of 431 recent VC-backed startup shutdowns shows failure isn't evenly spread. Three sectors account for roughly 40% of the total:

Healthcare & biotech: 14.4%
Fintech: 13.2%
Food & agriculture: 12.5%

Each fails for a genuinely different reason, which matters more than the ranking itself:

Healthcare & biotech also destroys the most capital of any sector — over $5B — because more than half the category is biotech, and clinical-stage drug development is binary by nature: a therapeutic either clears trials or it doesn't, after years and hundreds of millions of dollars are committed.

Fintech failures skew earlier-stage and more international, with typical funding well below the broader median, concentrated heavily in the 2021–2022 emerging-market fintech boom. These are unit-economics failures, not clinical failures — companies that scaled quickly on cheap capital and couldn't hold together once that capital tightened.

Food & agriculture is the more surprising entrant, driven largely by the alt-protein and cultivated meat unwind — well-funded companies riding a consumer trend that hadn't yet materialized at the scale or price point the funding assumed.

| Sector | Failure driver | Signature risk | |---|---|---| | Healthcare & biotech | Clinical/scientific risk | Binary, capital-intensive, priced in from day one | | Fintech | Funding-cycle risk | Early-stage, boom-bust capital, thin unit economics | | Food & agriculture | Trend/timing risk | Capital arriving ahead of real consumer demand |

Where We're Seeing Founders Build Right Now

That's where startups have already failed. Where are today's founders actually building? Our own Q3 2026 Venture Benchmark, drawn from real idea submissions on the Ekko validation platform, gives us a live read.

Founder interest this quarter split almost evenly between "Other" (45.9%) and AI & ML (43.2%), with B2B SaaS trailing well behind at 10.8%. None of the historically fragile sectors above — healthcare & biotech, fintech, food & ag — show up as dominant categories in what we're seeing come through our pipeline right now.

On its own, that might read as good news: founders avoiding the graveyard sectors. It isn't good news, and here's why.

The Viability Gap That Sector Choice Doesn't Fix

Of the ideas we scored this quarter, 71.4% landed in our lowest viability band (0–50), and zero scored above 90. 73% of founders submitted ideas with a vague target customer — "everyone," or no real definition at all. And 100% of validated ideas showed weak monetization and unclear distribution.

In other words: founders are moving away from the sectors with the worst historical failure rates, and building ideas that carry the exact same structural risk anyway. The sector on the pitch deck changed. The underlying problem — no defined customer, no clear path to revenue — didn't.

Sector Isn't the Variable. Validation Is.

This is the pattern we see over and over: a biotech founder's real risk is clinical data, a fintech founder's real risk is unit economics under tightening capital, and an AI founder's real risk today — where the most founder attention is currently concentrated — is building a genuinely defined solution for a defined customer, rather than a plausible-sounding idea riding the same kind of hype wave that sank alt-protein and NFT startups a few years ago.

None of these risks are visible from the sector label. They're only visible once you test the actual assumptions: who's buying, why now, and what they'll pay.

That's the test we built Ekko to run before a founder spends months building. A real, hosted landing page with a waitlist surfaces genuine buyer intent instead of guesses. A pre-mortem report builds the brutal case against the idea before it costs anything. A viability score tells you, honestly, whether the idea you're excited about is in that 71.4% or the smaller group actually worth building.

Check where your idea lands →

Key Takeaways

Healthcare & biotech, fintech, and food & agriculture account for ~40% of recent VC-backed shutdowns, each failing for a structurally different reason: clinical risk, funding-cycle risk, and trend-driven capital.
Healthcare & biotech destroys the most capital (over $5B) due to binary clinical trial risk; fintech skews early and international; food & ag's failures trace largely to the alt-protein unwind.
Our Q3 2026 founder data shows today's ideas concentrated in AI & ML, away from these historically fragile sectors — but that shift hasn't improved underlying idea quality.
71.4% of ideas we scored this quarter landed in the lowest viability band, with 73% carrying a vague target customer and 100% showing weak monetization — regardless of sector.
Sector doesn't predict survival. Validated demand and a clear monetization path do — and both are testable before you build.

Frequently asked

Questions, answered.

Which industries have the highest startup failure rate? Healthcare & biotech, fintech, and food & agriculture lead recent industry data on VC-backed shutdowns, together accounting for roughly 40% of all failures tracked — though each fails for a different underlying reason.

Does picking a "safer" sector reduce a startup's chance of failure? Not meaningfully. Our own founder data shows current ideas are concentrated away from the historically highest-failure sectors, in categories like AI & ML — yet 71.4% of those ideas still scored in our lowest viability band, because the underlying customer and monetization assumptions were never tested.

What actually predicts whether a startup will survive? A clearly defined target customer and a validated monetization path matter far more than which sector a company operates in. Both are things a founder can test before building, using a real landing page, a pre-mortem, and market research.

How can I check if my startup idea is viable before I build it? Ekko runs this check directly: describe your idea, and it ships a hosted landing page with a waitlist to collect real buyer intent, then generates a pre-mortem and a viability score so you know whether to build, pivot, or walk away — before spending months of engineering time finding out the hard way.